$32.51
1.93% yesterday
Nasdaq, Sep 27, 10:02 pm CET
ISIN
US87650L1035
Symbol
TARS
Sector
Industry

Tarsus Pharmaceuticals Inc Target price 2024 - Analyst rating & recommendation

Tarsus Pharmaceuticals Inc Classifications & Recommendation:

Buy
88%
Hold
13%

Tarsus Pharmaceuticals Inc Price Target

Target Price $59.00
Price $32.51
Potential
Number of Estimates 8
8 Analysts have issued a price target Tarsus Pharmaceuticals Inc 2025 . The average Tarsus Pharmaceuticals Inc target price is $59.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Tarsus Pharmaceuticals Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Tarsus Pharmaceuticals Inc stock has an average upside potential 2025 of . Most analysts recommend the Tarsus Pharmaceuticals Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 17.45 163.64
32.42% 837.79%
EBITDA Margin -815.36% -90.56%
240.00% 88.89%
Net Margin -1,006.87% -85.71%
171.27% 91.49%

6 Analysts have issued a sales forecast Tarsus Pharmaceuticals Inc 2024 . The average Tarsus Pharmaceuticals Inc sales estimate is

$164m
Unlock
. This is
96.29% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$168m 101.04%
Unlock
, the lowest is
$158m 89.28%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $17.5m 32.42%
2024
$164m 837.79%
Unlock
2025
$283m 73.04%
Unlock
2026
$511m 80.35%
Unlock
2027
$755m 47.84%
Unlock
2028
$890m 17.88%
Unlock

2 Analysts have issued an Tarsus Pharmaceuticals Inc EBITDA forecast 2024. The average Tarsus Pharmaceuticals Inc EBITDA estimate is

$-148m
Unlock
. This is
4.48% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-137m 11.52%
Unlock
, the lowest is
$-159m 2.56%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-142m 129.78%
2024
$-148m 4.16%
Unlock
2025
$-81.3m 45.17%
Unlock
2026
$10.8m 113.29%
Unlock

EBITDA Margin

2023 -815.36% 240.00%
2024
-90.56% 88.89%
Unlock
2025
-28.70% 68.31%
Unlock
2026
2.11% 107.35%
Unlock

5 Tarsus Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Tarsus Pharmaceuticals Inc net profit estimate is

$-140m
Unlock
. This is
17.68% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-129m 24.33%
Unlock
, the lowest is
$-152m 10.94%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-176m 83.33%
2024
$-140m 20.18%
Unlock
2025
$-97.2m 30.70%
Unlock
2026
$53.1m 154.65%
Unlock
2027
$200m 276.94%
Unlock
2028
$327m 63.15%
Unlock

Net Margin

2023 -1,006.87% 171.27%
2024
-85.71% 91.49%
Unlock
2025
-34.33% 59.95%
Unlock
2026
10.40% 130.29%
Unlock
2027
26.52% 155.00%
Unlock
2028
36.71% 38.42%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -4.62 -3.69
83.33% 20.13%
P/E negative
EV/Sales 6.02

5 Analysts have issued a Tarsus Pharmaceuticals Inc forecast for earnings per share. The average Tarsus Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-3.69
Unlock
. This is
17.63% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-3.39 24.33%
Unlock
, the lowest is
$-3.99 10.94%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-4.62 83.33%
2024
$-3.69 20.13%
Unlock
2025
$-2.56 30.62%
Unlock
2026
$1.40 154.69%
Unlock
2027
$5.27 276.43%
Unlock
2028
$8.59 63.00%
Unlock

P/E ratio

Current -7.25 45.58%
2024
-8.82 21.66%
Unlock
2025
-12.72 44.22%
Unlock
2026
23.28 283.02%
Unlock
2027
6.17 73.50%
Unlock
2028
3.78 38.74%
Unlock

Based on analysts' sales estimates for 2024, the Tarsus Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 11.82 63.03%
2024
6.02 49.06%
Unlock
2025
3.48 42.21%
Unlock
2026
1.93 44.55%
Unlock
2027
1.31 32.36%
Unlock
2028
1.11 15.17%
Unlock

P/S ratio

Current 14.83 66.46%
2024
7.56 49.05%
Unlock
2025
4.37 42.21%
Unlock
2026
2.42 44.55%
Unlock
2027
1.64 32.35%
Unlock
2028
1.39 15.17%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today